Longevity & AgingPress Release

Alzheimer's May Shrink Two Brain Regions a Decade Before Memory Loss Begins

Johns Hopkins scans suggest the entorhinal cortex and amygdala shrink before the hippocampus, possibly flagging Alzheimer's up to 10 years before symptoms.

Sunday, November 15, 2026 0 views
Published in ScienceDaily Aging
Article visualization: Alzheimer's May Shrink Two Brain Regions a Decade Before Memory Loss Begins

Summary

Alzheimer's disease may leave detectable marks in the brain up to a decade before memory problems show up. Johns Hopkins researchers analyzed hundreds of brain scans (MRI and PET) from two independent research cohorts. They found that the entorhinal cortex and the amygdala, regions involved in memory and emotion, begin losing tissue earlier than the hippocampus, the area doctors usually examine for Alzheimer's-related shrinkage. These early changes were linked to abnormal buildup of tau protein, a hallmark of the disease. The findings, published in NeuroImage Reports and presented at Neuroscience 2026, point toward better imaging markers for spotting people at risk well before symptoms. The hope is that treatment could begin years earlier, when it has the greatest chance of protecting memory and thinking. This is early-stage research on detection, not a treatment, and it does not yet change what you can do today.

Detailed Summary

Alzheimer's disease is the most common cause of dementia worldwide, yet it does not begin when forgetfulness first appears. Changes build silently in the brain for decades, and by the time memory symptoms emerge, substantial damage has often already occurred. That is why researchers are searching for reliable biomarkers that can reveal the disease in its earliest stages, when interventions may have the best chance of preserving cognition.

Researchers at Johns Hopkins University examined hundreds of MRI and PET scans drawn from two independent research projects: the Alzheimer's Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study. They found that the entorhinal cortex and the amygdala, two regions tied to memory and emotion, begin losing tissue earlier than the hippocampus. The hippocampus is the structure clinicians typically look at when evaluating atrophy linked to Alzheimer's. According to senior author Michael Miller, measurable atrophy can appear as much as a decade before clinical symptoms.

The early shrinkage in these two regions was linked to abnormal tau protein accumulation, one of the defining pathological features of Alzheimer's. This suggests that structural imaging of the entorhinal cortex and amygdala could capture the disease process sooner than hippocampal measurements alone. The authors describe a window of roughly five to ten years in which the brain is changing but symptoms have not yet developed.

The practical promise is earlier identification of people at risk, which could allow treatment to start at, for example, the two- to four-year point rather than after about fifteen years of change. Marilyn Albert, a co-author, said the goal is to treat before symptoms develop so that the disease can be delayed or even stopped.

Several caveats apply. The work concerns detection, not treatment, and no therapy is shown to work better when started earlier based on these results. Brain imaging measures need validation for individual-level prediction, not just group patterns. The findings were reported through a press release, so readers should consult the NeuroImage Reports paper for effect sizes, sample details, and how well the measures distinguish people who will develop Alzheimer's from those who will not.

Key Findings

  • Entorhinal cortex and amygdala appear to shrink before the hippocampus, the region most often checked for Alzheimer's atrophy.
  • Measurable brain atrophy may precede memory symptoms by roughly 5 to 10 years, according to the senior author.
  • Early shrinkage in these two regions was linked to abnormal tau protein accumulation seen on PET imaging.
  • Analysis drew on hundreds of MRI and PET scans from two independent research cohorts.
  • The goal is earlier risk identification so treatment could begin years before symptoms appear.

Methodology

This is a university press release republished as a science news item, summarizing a peer-reviewed study in NeuroImage Reports. The evidence comes from imaging analysis (MRI and PET) of hundreds of scans from two established research cohorts. The excerpt gives no sample size details, effect sizes, or statistical methods.

Study Limitations

The article is a press summary and was truncated, so details on participants, accuracy of prediction, and how tau was measured are missing. Group-level imaging differences do not guarantee reliable individual prediction, and early detection has not been shown to improve outcomes. Check the NeuroImage Reports paper for full methods and results.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: